Why the study?
Evidence was limited regarding high on-treatment platelet reactivity and its genetic determinants in predicting clinical outcomes of stroke among Chinese-Han patients.
Does high on-treatment platelet reactivity or CYP2C19/P2Y12 gene polymorphism predict recurrent ischemic events in Chinese-Han patients with acute ischemic stroke treated with clopidogrel?
Population
131 Chinese-Han stroke patients treated with clopidogrel
Comparison
Patients with HTPR vs without HTPR and CYP2C19 LOF carriers vs wild-type homozygotes
Design
Prospective study
Authors
Loading...
Extends HTPR assessment to Chinese-Han stroke patients on clopidogrel; leaves open whether it outperforms genotyping for outcomes.
Does high on-treatment platelet reactivity or CYP2C19/P2Y12 gene polymorphism predict recurrent ischemic events in Chinese-Han patients with acute ischemic stroke treated with clopidogrel?
In Chinese-Han patients with acute ischemic stroke, high on-treatment platelet reactivity to clopidogrel predicts recurrent ischemic events, whereas CYP2C19 loss-of-function alleles predict HTPR but not clinical prognosis.
Fu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: